Title: A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors Session Type: Poster Session Session Title: Developmental Therapeutics ...

Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381. News provided by. Rakuten Medical, Inc.

As shown in Figure 1, after 5 years of follow-up, the Kaplan-Meier estimated 5-year DFS rate in the 46 HER2 3+ patients treated with GP2+GM-CSF, if the patient completed the PIS, was 100% versus ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress, ELCC, 2025, taking place in Paris ...

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...

TORREY PINES, Calif., June 1, 2022 /PRNewswire/ -- EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of devel ...

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology ... heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.

Flamingo Therapeutics ("Flamingo") today announced that an abstract has been accepted for presentation at the American Association for Cancer Research (AACR) annual meeting being held in Chicago ...

Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381 Provided by PR Newswire May 22, 2025, 11:05:00 PM ...